Who are Valsartan+/- Hydrochlorothiazide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): placebo/valsartan, Olmesartan medoxomil tablets, Cozzar tablet, Irbesartan Oral Tablet, Irbesartan (Aprovel), Valsartan Capsules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/valsartan-hydrochlorothiazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Valsartan+/- Hydrochlorothiazide — Competitive Intelligence Brief

Valsartan+/- Hydrochlorothiazide (Valsartan+/- Hydrochlorothiazide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable. Area: Cardiovascular.

marketed Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (thiazide component) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Valsartan+/- Hydrochlorothiazide (Valsartan+/- Hydrochlorothiazide) — Novartis. Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure, while hydrochlorothiazide (when present) acts as a thiazide diuretic to reduce fluid volume.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Valsartan+/- Hydrochlorothiazide TARGET	Valsartan+/- Hydrochlorothiazide	Novartis	marketed	Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (thiazide component)
placebo/valsartan	placebo/valsartan	Medical University of Silesia	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Olmesartan medoxomil tablets	Olmesartan medoxomil tablets	Lee's Pharmaceutical Limited	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Cozzar tablet	Cozzar tablet	Chong Kun Dang Pharmaceutical	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Irbesartan Oral Tablet	Irbesartan Oral Tablet	University of Southern Denmark	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Irbesartan (Aprovel)	Irbesartan (Aprovel)	Sanofi	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Valsartan Capsules	Valsartan Capsules	Affiliated Hospital of Nantong University	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable class)

Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Valsartan+/- Hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-hydrochlorothiazide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab